(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 June 2003 (05.06.2003)

PCT

(10) International Publication Number
WO 03/045437 A1

(51) International Patent Classification[7]: A61K 47/38, 47/36, 47/02, 47/10, 31/495

(21) International Application Number: PCT/IB02/04612

(22) International Filing Date:
4 November 2002 (04.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/334,652 30 November 2001 (30.11.2001) US

(71) Applicant *(for all designated States except US)*: **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **AM ENDE, Mary, Tanya** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **ROY, Michael, Christopher** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **SMITH, Scott, Wendell** [US/US]; Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121 (US). **WATERMAN, Kenneth, Craig** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **MOSES, Sara, Kristen** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **QUAN, Ernest, Shing** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US).

(74) Agents: **LUMB, J., Trevor** et al.; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(48) Date of publication of this corrected version:
14 August 2003

(15) Information about Correction:
see PCT Gazette No. 33/2003 of 14 August 2003, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/045437 A1

(54) Title: PHARMACEUTICAL COMPOSITIONS OF 5,7,14-TRIAZATETRACYCLO[10.3.1.0(2,11).0(4,9)]-HEXADECA-2(11)3,5,7,9-PENTAENE



(I)

(57) Abstract: The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of 5,8,14-triazatetracyclo[10.3.1.$0^{2,11}$.$0^{4,9}$]-hexadeca-2(11),3,5,7,9-pentaene, 1, and pharmaceutically acceptable salts thereof, and methods of using them to reduce nicotine addiction or aiding in the cessation or lessening of tobacco use while reducing nausea as an adverse effect. The present invention also relates to an immediate-release (IR) low dosage composition having a stable formulation with uniform drug distribution and potency.